Skip to main content
Terug
TBPH logo

Theravance Biopharma, Inc.

Datakwaliteit: 100%
TBPH
NASDAQ Healthcare Biotechnology
€ 14,75
▲ € 0,42 (2,93%)
Marktkapitalisatie: 747,42M
Dagbereik
€ 14,52 € 14,93
52-Weeksbereik
€ 7,90 € 21,03
Volume
878.908
50D / 200D Gem.
€ 17,97 / € 15,18
Vorige Slotkoers
€ 14,33

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 7,1 0,4
P/B 2,5 2,9
ROE % 44,9 3,7
Net Margin % 98,5 3,8
Rev Growth 5Y % 18,1 10,0
D/E 0,1 0,2

Insider Trading Activity

17 transactions
Date Insider Type Shares Price Value
Feb 20, 2026
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 74.975 € 19,66 € 1.474.009
Feb 20, 2026
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 20.672 € 19,66 € 406.412
Feb 20, 2026
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 13.929 € 19,66 € 273.844
Feb 20, 2026
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
 other 16.851 € 19,66 € 331.291
Nov 20, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 9.060 € 17,90 € 162.174
Nov 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 56.817 € 17,90 € 1.017.024
Nov 19, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 19.800 — —
Aug 20, 2025
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 9.368 € 13,39 € 125.438
Aug 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 15.394 € 13,39 € 206.126
Aug 20, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 other 9.096 € 13,39 € 121.795
Aug 20, 2025
Miller Aine
SVP, DEV & HEAD OF IRE OFFICE
 other 6.989 € 13,39 € 93.583
Jun 23, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 20.000 — —
Jun 2, 2025
Farnum Rhonda
SVP, COMM & MEDICAL AFFAIRS
 sell 24.000 € 11,00 € 264.000
May 20, 2025
Sawaf Aziz
SVP & CHIEF FINANCIAL OFFICER
 other 9.348 € 9,45 € 88.339
May 20, 2025
Winningham Rick E
CHIEF EXECUTIVE OFFICER
 other 15.364 € 9,45 € 145.190
May 19, 2025
GRAY SUSANNAH
 grant 34.907 — —
May 19, 2025
Smaldone Alsup Laurie
 grant 34.907 — —

Belangrijkste Punten

Revenue grew 18,06% annually over 5 years — strong growth
ROE of 44,85% indicates high profitability
Net margin of 98,54% shows strong profitability
Debt/Equity of 0,14 — conservative balance sheet
Generating 238,50M in free cash flow
P/E of 7,06 — trading at a low valuation

Groei

Revenue Growth (5Y)
18,06%
Revenue (1Y)66,92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
44,85%
ROIC-0,80%
Net Margin98,54%
Op. Margin-3,35%

Veiligheid

Debt / Equity
0,14
Current Ratio10,93
Interest Coverage-1,46

Waardering

P/E Ratio
7,06
P/B Ratio2,52
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 66,92% Revenue Growth (3Y) 36,80%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 18,06% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 107,46M Net Income (TTM) 105,90M
ROE 44,85% ROA 21,81%
Gross Margin 0,00% Operating Margin -3,35%
Net Margin 98,54% Free Cash Flow (TTM) 238,50M
ROIC -0,80% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,14 Current Ratio 10,93
Interest Coverage -1,46 Dividend Yield 0,00%
Valuation
P/E Ratio 7,06 P/B Ratio 2,52
P/S Ratio 6,96 PEG Ratio -0,03
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 747,42M Enterprise Value 622,32M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 107,46M 64,38M 57,42M 51,35M 55,31M
Net Income 105,90M -56,42M -55,19M 872,13M -199,43M
EPS (Diluted) 2,06 -1,15 -1,00 -1,26 -2,87
Gross Profit 0,0 64,38M 16,80M -12,05M -138,35M
Operating Income -3,60M -46,95M -56,04M -91,96M -257,78M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 485,57M 354,16M 382,00M 607,40M 374,82M
Total Liabilities 188,85M 178,62M 169,00M 165,60M 713,39M
Shareholders' Equity 296,72M 175,55M 213,00M 441,80M -338,57M
Total Debt 42,70M 49,82M 49,16M 52,16M 669,52M
Cash & Equivalents 167,81M 37,80M 39,55M 298,17M 89,96M
Current Assets 418,46M 161,07M 133,54M 353,46M 249,87M
Current Liabilities 38,30M 32,09M 24,77M 28,72M 58,59M

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#156 of 1024
65
Custom Capital Light Compounder
#7 of 213
75
Custom Contrarian Investing (David Dreman)
#29 of 658
79
Value Value Investing (Warren Buffett)
#9 of 195
62

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Value Investing (Warren Buffett)
Mar 24, 2026